<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02166827</url>
  </required_header>
  <id_info>
    <org_study_id>NRX-LT1</org_study_id>
    <nct_id>NCT02166827</nct_id>
  </id_info>
  <brief_title>Effects of a NeuroAD System, for the Treatment of Alzheimer Disease</brief_title>
  <official_title>Effects of a NeuroAD System, for the Treatment of Alzheimer Disease: a Randomized, Double-blinded, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuronix Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuronix Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the long-term efficacy of the NeuroAD system
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the long-term efficacy of the NeuroAD system in improvement of mild- to moderate
      Alzheimer patients' cognitive function
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administrative decision
  </why_stopped>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>3 Months</time_frame>
    <description>Change from Baseline to 3 months in ADAS-Cog score and CGI-C. ADAS-Cog: Alzheimer's Disease Assessment Scale - Cognitive. CGI-C: Clinical Global Impression of Change</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>7 weeks</time_frame>
    <description>Change from Baseline to week 7 in ADAS-Cog score and CGI-C. ADAS-Cog: Alzheimer's Disease Assessment Scale - Cognitive. CGI-C: Clinical Global Impression of Change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>6 Months</time_frame>
    <description>Change from Baseline to 6 months in ADAS-Cog score and CGI-C. ADAS-Cog: Alzheimer's Disease Assessment Scale - Cognitive. CGI-C: Clinical Global Impression of Change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>9 Months</time_frame>
    <description>Change from Baseline to 9 months in ADAS-Cog score and CGI-C. ADAS-Cog: Alzheimer's Disease Assessment Scale - Cognitive. CGI-C: Clinical Global Impression of Change</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety</measure>
    <time_frame>9 Months</time_frame>
    <description>Adverse events (AE's), including serious adverse events (SAEs) occurring at any time during the trial and follow-up</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>NeuroAD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NeuroAd Treatment, synchronized TMS and cognitive training stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham TMS+Cog</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeuroAD</intervention_name>
    <description>Synchronized TMS and cognitive stimulation to 6 brain areas.</description>
    <arm_group_label>NeuroAD</arm_group_label>
    <other_name>NICE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham TMS+Cog</intervention_name>
    <description>Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises.</description>
    <arm_group_label>Sham TMS+Cog</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Male or female age 60-90 years

          2. Patients diagnosed with mild or moderate stage of Alzheimer's Disease, according to
             the DSM-IV criteria

          3. MMSE score 18 to 26

          4. Physical clearance for study participation as evaluated by the clinician

          5. Spouse, family member or professional caregiver agree and capable of taking care for
             the participation of the patient in the study (answering questions regarding the
             patient's condition and assuming responsibility for medication)

          6. Informed consent by the patient or by legally authorized person if appointed

        Main Exclusion Criteria:

          1. CDR 0, 0.5 or 3

          2. Severe agitation

          3. Mental retardation

          4. History of Epileptic Seizures or Epilepsy

          5. Contraindication for performing MRI scanning

          6. Contraindication for receiving TMS treatment according to a TMS questionnaire

          7. Patients with metal implants in the head, (i.e. cochlear implants, implanted brain
             stimulators and neurostimulators, aneurysm clips) with the exception of metal implants
             in mouth

          8. Cardiac pacemakers

          9. Implanted medication pumps

         10. Intracardiac lines

         11. Significant heart disease

         12. Currently taking medication that lower the seizure threshold
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shaare Zedek</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://neuronixmedical.com/</url>
    <description>Sponsor's website</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2014</study_first_submitted>
  <study_first_submitted_qc>June 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <last_update_submitted>March 30, 2017</last_update_submitted>
  <last_update_submitted_qc>March 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TMS</keyword>
  <keyword>Cognitive Stimulation</keyword>
  <keyword>NeuroAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

